Core Viewpoint - Xenetic Biosciences, Inc. announced the adjournment of its 2025 Annual Meeting of Stockholders due to a lack of quorum, urging stockholders who have not voted to participate in the reconvened meeting scheduled for January 8, 2026 [1][2]. Company Information - Xenetic Biosciences is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies aimed at treating difficult cancers [8][9]. - The company's proprietary DNase technology targets neutrophil extracellular traps (NETs) involved in cancer progression, with a focus on developing systemic DNase as an adjunctive therapy for pancreatic carcinoma and other solid tumors [8][9]. Meeting Details - The Annual Meeting was adjourned because fewer than a majority of the outstanding shares entitled to vote were present [2]. - The reconvened Annual Meeting will take place virtually on January 8, 2026, at 10:00 a.m. Eastern Time [2]. - Stockholders who have already voted do not need to vote again, as their previous votes will remain valid [3]. Voting Information - Stockholders eligible to vote must do so by 11:59 p.m. Eastern Time on January 7, 2026, and can vote online or by telephone [4]. - The record date for determining eligible stockholders remains October 15, 2025 [3][4]. Proxy Statement - A definitive proxy statement was filed with the SEC on October 31, 2025, and is available for stockholders to review [7].